



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Dr. Roland Herzog Ph.D.

Committee: Cellular Tissue and Gene Therapies Advisory Committee (CTGTAC)

Meeting Date: September 2-3, 2021

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the meeting topic: The CTGTAC committee will meet in open session on both days to discuss the toxicity risks of adeno-associated virus (AAV) vector-based gene therapy products. The discussion topics include oncogenicity risks due to vector genome integration and safety issues identified during preclinical and/or clinical evaluation. I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
N/A	N/A	N/A
II. Other Imputed Interests		
Contracts/Grants	Employer's research funded by NIH	\$1,000,000 -- \$1,100,000, per year
Contracts/Grants	Employer's research funded by NIH	\$250,000 -- \$300,000 per year
Contracts/Grants	Employer's research funded by NIH	\$350,000 -- \$400,000 per year
Contracts/Grants	Employer's research funded by NIH	\$1,000,000 -- \$1,100,000 per year
Contract Under Negotiation	Affected Entity	TBD

U.S. Food & Drug
Administration
10903 New Hampshire
Avenue Silver Spring, MD
20993
www.fda.gov

Page 2 of 2

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

-----S-----

8/13/21

Signature

Date